Up-regulation of several of these immune mediators (IL-6, IL-8, and MCP-1) was previously reported in liver cells and/or plasma of patients with steatosis and NASH, and correlated positively with the severity of liver inflammation and fibrosis (36–38). Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.